Responsible Care
02-déc.-2009
Développement d'un nouvel anticorps BiTE pour le traitement des tumeurs solides:
Bayer Schering Pharma va travailler avec Micromet sur une nouvelle approche de thérapie pour le cancer
Bayer Schering Pharma AG, en Allemagne, va développer Germany, will develop a new BiTE antibody for
the treatment of solid tumors in collaboration with the biopharmaceutical company Micromet, Inc. In
January 2009, both companies had entered into an option, license and collaboration agreement. By
exercising the option now, Bayer Schering Pharma has triggered a joint collaboration on the
development of the BiTE antibody against an undisclosed solid tumor target through the completion
of Phase I clinical trials, at which point Bayer will assume full control of the further
development and commercialization of the antibody. BiTE antibodies are designed to direct the
body's cell-destroying T cells against tumor cells, and represent a new therapeutic approach to
cancer therapy
Développement d'un nouvel anticorps BiTE pour le traitement des tumeurs solides:
Bayer Schering Pharma va travailler avec Micromet sur une nouvelle approche de thérapie pour le cancer